Logo

Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

Share this

Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

Shots:

  • Arvinas’ ARV-110 is an orally available PROTAC protein degrader used for targeting androgen receptor (AR) protein and is currently evaluated in P-I for its safety- tolerability- and PK in men with 2L+ mCRPC
  • In Q1’19- Arvinas initiated its P-I study of ARV-110 for mCRPC with its preliminary clinical data sharing in H2’19 and expected full disclosure of study in H1’20
  • Arvinas’ PROTAC protein degraders (Proteolysis-Targeting Chimera) are used for harnessing body’s immune system to degrade disease-causing proteins with the help of E3 ligase for tagging the protein with ubiquitin- further leading to its degradation through proteasome

Ref: Arvinas | Image: The Pharma Letter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions